Literature DB >> 9780534

Cost-effectiveness of open versus laparoscopic repair for primary inguinal hernia.

C D Dirksen1, A J Ament, E M Adang, G L Beets, P M Go, C G Baeten, G Kootstra.   

Abstract

A cost-effectiveness (CE) analysis was performed of Bassini versus laparoscopic repair for primary inguinal hernia. Incremental costs per 1-year recurrence-free patient were calculated for the societal and hospital perspective. From the hospital perspective, the incremental CE ratio of laparoscopic repair is 5.348 guilders. From the societal perspective, laparoscopic repair is both less costly and more effective than Bassini repair. Results were sensitive to assumptions about recurrence rates, laparoscopic operating time, and return to work. Laparoscopic repair should replace Bassini repair in order to benefit society. From the hospital perspective, the decision to accept laparoscopic repair depends on the willingness to pay.

Entities:  

Mesh:

Year:  1998        PMID: 9780534     DOI: 10.1017/s0266462300011454

Source DB:  PubMed          Journal:  Int J Technol Assess Health Care        ISSN: 0266-4623            Impact factor:   2.188


  4 in total

1.  Comparison of endoscopic techniques vs Shouldice and other open nonmesh techniques for inguinal hernia repair: a meta-analysis of randomized controlled trials.

Authors:  R Bittner; S Sauerland; C-G Schmedt
Journal:  Surg Endosc       Date:  2005-03-28       Impact factor: 4.584

2.  International guidelines for groin hernia management.

Authors: 
Journal:  Hernia       Date:  2018-01-12       Impact factor: 4.739

Review 3.  Estimating productivity costs using the friction cost approach in practice: a systematic review.

Authors:  Jesse Kigozi; Sue Jowett; Martyn Lewis; Pelham Barton; Joanna Coast
Journal:  Eur J Health Econ       Date:  2014-11-12

Review 4.  The role of endoscopic extraperitoneal herniorrhaphy: where do we stand in 2005?

Authors:  W B Bowne; C B Morgenthal; A E Castro; P Shah; G S Ferzli
Journal:  Surg Endosc       Date:  2007-02-06       Impact factor: 3.453

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.